NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
fatty liver
hepatic fibrosis
inflammation
nonalcoholic steatohepatitis
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
27
04
2021
accepted:
06
02
2022
pubmed:
3
4
2022
medline:
10
11
2022
entrez:
2
4
2022
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) can persist in the stage of simple hepatic steatosis or progress to steatohepatitis (NASH) with an increased risk for cirrhosis and cancer. We examined the mechanisms controlling the progression to severe NASH in order to develop future treatment strategies for this disease. NFATc1 activation and regulation was examined in livers from patients with NAFLD, cultured and primary hepatocytes and in transgenic mice with differential hepatocyte-specific expression of the transcription factor ( NFATc1 expression was weak in healthy livers but strongly induced in advanced NAFLD stages, where it correlates with liver enzyme values as well as hepatic inflammation and fibrosis. Moreover, high-fat WD increased NFATc1 expression, nuclear localisation and activation to promote NAFLD progression, whereas hepatocyte-specific depletion of the transcription factor can prevent mice from disease acceleration. Mechanistically, NFATc1 drives liver cell damage and inflammation through ER stress sensing and activation of the PERK-CHOP unfolded protein response (UPR). Finally, NFATc1-induced disease progression towards NASH can be blocked by TUDCA administration. NFATc1 stimulates NAFLD progression through chronic ER stress sensing and subsequent activation of terminal UPR signalling in hepatocytes. Interfering with ER stress-responses, for example, by TUDCA, protects fatty livers from progression towards manifest NASH.
Identifiants
pubmed: 35365570
pii: gutjnl-2021-325013
doi: 10.1136/gutjnl-2021-325013
pmc: PMC9664107
doi:
Substances chimiques
ursodoxicoltaurine
60EUX8MN5X
Transcription Factors
0
Nfatc1 protein, mouse
0
NFATC Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2561-2573Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Cell Rep. 2018 Sep 11;24(11):2985-2999
pubmed: 30208322
Mol Cell Endocrinol. 2015 Sep 15;413:189-201
pubmed: 26135354
EMBO J. 2015 Feb 12;34(4):517-30
pubmed: 25586376
Cancer Discov. 2014 Jun;4(6):688-701
pubmed: 24694735
Front Mol Biosci. 2019 Mar 12;6:11
pubmed: 30931312
Immunity. 2015 Sep 15;43(3):451-62
pubmed: 26341399
J Cell Physiol. 2019 Feb 11;:
pubmed: 30746697
Hepatology. 2008 Dec;48(6):1932-41
pubmed: 18846549
Curr Mol Med. 2013 May;13(4):543-54
pubmed: 22950383
Hepatology. 2002 Sep;36(3):525-31
pubmed: 12198643
Medicine (Baltimore). 2016 Nov;95(47):e5391
pubmed: 27893675
Nat Rev Cancer. 2009 Nov;9(11):810-20
pubmed: 19851316
J Hepatol. 2020 Dec;73(6):1333-1346
pubmed: 32717288
J Clin Invest. 2008 Nov;118(11):3775-89
pubmed: 18846253
Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60
pubmed: 21440669
Gastroenterology. 2015 May;148(5):1024-1034.e9
pubmed: 25623042
J Pathol. 2016 Mar;238(4):531-42
pubmed: 26415102
Annu Rev Pathol. 2008;3:399-425
pubmed: 18039139
J Hepatol. 2018 Oct;69(4):927-947
pubmed: 29940269
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
QJM. 2010 Feb;103(2):71-83
pubmed: 19914930
Clin Exp Gastroenterol. 2014 Jul 05;7:221-39
pubmed: 25045276
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nature. 2006 Sep 21;443(7109):345-9
pubmed: 16988714
Semin Liver Dis. 2019 May;39(2):235-248
pubmed: 30912096
Nat Cell Biol. 2019 Mar;21(3):328-337
pubmed: 30778220
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Gastroenterology. 2017 May;152(6):1507-1520.e15
pubmed: 28188746
J Hepatol. 2011 Apr;54(4):795-809
pubmed: 21145844
Toxicol Sci. 2014 Jan;137(1):26-35
pubmed: 24097666
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Sci Rep. 2017 Jun 19;7(1):3831
pubmed: 28630443
EMBO J. 2019 Aug 1;38(15):e100871
pubmed: 31304984
Sci Rep. 2018 Jul 27;8(1):11365
pubmed: 30054551
EMBO J. 2006 Aug 9;25(15):3714-24
pubmed: 16874304
Hepatology. 2011 Jul;54(1):133-44
pubmed: 21488066
World J Gastroenterol. 2014 Nov 14;20(42):15539-48
pubmed: 25400438
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16638-16648
pubmed: 32601188
Cell Death Dis. 2015 Sep 10;6:e1879
pubmed: 26355342
Dig Dis Sci. 2012 Dec;57(12):3184-8
pubmed: 22722879
J Mol Med (Berl). 2014 Oct;92(10):1069-82
pubmed: 24861026
J Biol Chem. 2016 Apr 15;291(16):8709-20
pubmed: 26903518
Front Endocrinol (Lausanne). 2018 Aug 24;9:485
pubmed: 30197624
PLoS One. 2015 May 27;10(5):e0127991
pubmed: 26017539
J Clin Invest. 2012 Oct;122(10):3476-89
pubmed: 22945633
Liver Res. 2019 Mar;3(1):55-64
pubmed: 32670671
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Cancer Cell. 2014 Sep 8;26(3):331-343
pubmed: 25132496
Oncogene. 2014 Apr 3;33(14):1840-9
pubmed: 23624921
Microbes Infect. 2009 Apr;11(5):612-9
pubmed: 19375514
Int J Cancer. 2014 Apr 15;134(8):1767-75
pubmed: 23775822
BMC Biochem. 2016 Mar 24;17:8
pubmed: 27009139
J Dairy Sci. 2019 Aug;102(8):7359-7370
pubmed: 31155263
J Gastroenterol Hepatol. 2014 May;29(5):1109-18
pubmed: 24329600